A Phase II, open-label study of ponatinib, a multi-targeted oral tyrosine kinase inhibitor, in advanced non-small-cell lung cancer harboring RET translocations

UCI-12-44
NCT01813734
Cancer - Lung
Sai-Hong Ignatius Ou
Open
Treatment
II
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.